Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2012

View Archived Issues

Mitsubishi Tanabe Pharma offers overview of second quarter 2012

Encouraging phase III results presented for Biocon's insulin biosimilar

Cubist Pharmaceuticals begins phase III program for CB-5945

European Commission denies marketing authorization for taliglucerase alfa

Phase I results reported for ICT-107 in glioblastoma multiforme

British and French group presents novel vaccines for AIDS

Qilu Pharmaceutical discloses novel EGFR inhibitors

Shanghai Allist Pharmaceutical patents new PI3K inhibitors

Novel tyrosine-protein kinase inhibitors prepared at Pharmascience

Phase II study of GS-7340 meets 24-week primary objective

Lundbeck prepares new antibodies for Alzheimer's disease

New CSF-1 receptor inhibitors divulged by Pharmascience

Sanofi presents pipeline highlights of third quarter 2012

Degarelix evaluated in women undergoing in vitro fertilization

Immune Response BioPharma publishes full results from phase III study of HIV vaccine

Vertex enters agreements for VX-135 combination studies

Lisdexamfetamine mesilate proves beneficial in cognitively impaired MS patients

FDA requests additional information in CRL for lixivaptan NDA

AlphaCore obtains EMA orphan drug designation for ACP-501

Aerie reports topline data from phase IIa studies of its ROCK inhibitors

Glybera gene therapy approved by the European Commission

Hutchison MediPharma begins phase I study of novel EGFR inhibitor

BAX B-01 shows promise in model of proliferative nephritis

Phase III trial of Adcetris in advanced Hodgkin's lymphoma begins

Keryx Biopharmaceuticals commences phase II study of Zerenex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...